http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104055759-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 |
| filingDate | 2014-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104055759-B |
| titleOfInvention | A kind of pharmaceutical composition and application thereof |
| abstract | The present invention relates to technical field of pharmaceuticals, particularly relate to a kind of pharmaceutical composition and application thereof.The pharmaceutical composition that the present invention provides includes: tomoxetine hydrochloride and taurine.The two combination can produce synergistic function.The present invention is found through experiments; contrast individually gives tomoxetine hydrochloride; taurine is used to be combined with tomoxetine hydrochloride; can more dramatically increase SOD activity and GSH content in juvenile stage ADHD rat model cerebral tissue, lower MDA content (P < 0.01); serve antioxidative effect; improve DBH and TH in juvenile stage ADHD rat model brain to express, raise Fos protein expression (P < 0.01) in Prefrontal Cortex cortex.Compared with individually dosed, the effect of pharmaceutical composition becomes apparent from.Therefore, the pharmaceutical composition of the present invention can be as the drug candidate for the treatment of hyperkinetic syndrome. |
| priorityDate | 2014-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 202.